Last edition
News about
Ministry of Ayush and DBT Launch Clinical Study on Ayurveda for TB Treatment
Ministry of Ayush and DBT launch a clinical study on Ayurveda as adjunct therapy for tuberculosis (TB), advancing evidence-based, integrative approaches to strengthen India’s TB elimination efforts.
Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial
Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.
The strategic collaboration between Biocytogen Pharmaceuticals Beijing and Moonlight Bio aims to combine antibody discovery and cell therapy expertise to develop innovative treatments for hard-to-treat cancers.
PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan
Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Lupin Gets US FDA Tentative Approval for Pitolisant Tablets
US FDA grants tentative approval to Lupin’s Pitolisant Tablets (4.45 mg, 17.8 mg), bioequivalent to Wakix, for approved indications.
Novartis Presents New Data on Skin Disease Treatment at AAD 2026
Novartis presents new AAD 2026 data showing early symptom relief and long-term control in skin diseases, with Rhapsido REMIX analysis in CSU and Cosentyx data in hidradenitis suppurativa and psoriasis.
Discovery Life Sciences and Mindpeak Partner for AI Cancer Biomarker Testing
Discovery Life Sciences and Mindpeak partner to bring AI-driven cancer biomarker testing in global clinical trials, aiming to reduce variability in biomarker interpretation and improve accuracy in drug development.
Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron
The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.
Merck & Co. is reportedly nearing a USD 6 billion acquisition of Terns Pharmaceuticals, as part of its strategy to strengthen its oncology portfolio and prepare for future growth.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy